Literature DB >> 21901599

Antibody microarrays as tools for biomarker discovery.

Marta Sanchez-Carbayo1.   

Abstract

The cancer biomarkers field is being enriched by molecular profiling obtained by high-throughput approaches. Targeted antibody arrays are strongly contributing to the identification of protein cancer -biomarker candidates and functional proteomic analyses. Due to their versatility, novel technological and experimental design implementations are broadening the applications of antibody arrays. However, the cancer biomarker candidates delivered to date using this technology are still in their early developmental phase, requiring validation with high number of specimens focusing on specific clinical endpoints. Innovative strategies multiplexing protein measurements of protein extracts of cultured cells, tissue and body fluids using antibody arrays combined with appropriate validation approaches are enabling the -discovery of cancer-associated biomarkers. This review describes these strategies and cancer biomarker candidates reported to date that may assist in the diagnosis, surveillance, prognosis, and potentially for predictive and therapeutic purposes for patients affected with solid and hematological neoplasias.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901599     DOI: 10.1007/978-1-61779-286-1_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA).

Authors:  Sabine Bader; Magdalena Zajac; Thomas Friess; Elisabeth Ruge; Natascha Rieder; Berthold Gierke; Yvonne Heubach; Marlene Thomas; Michael Pawlak
Journal:  Mol Cell Proteomics       Date:  2015-06-23       Impact factor: 5.911

2.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 3.  COVID-19 Diagnostic Strategies Part II: Protein-Based Technologies.

Authors:  Tina Shaffaf; Ebrahim Ghafar-Zadeh
Journal:  Bioengineering (Basel)       Date:  2021-04-28

4.  History and structures of telecommunication in pathology, focusing on open access platforms.

Authors:  Klaus Kayser; Stephan Borkenfeld; Amina Djenouni; Gian Kayser
Journal:  Diagn Pathol       Date:  2011-11-07       Impact factor: 2.644

5.  Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.

Authors:  Manuel Puig-Costa; Antonio Codina-Cazador; Elisabet Cortés-Pastoret; Cristina Oliveras-Ferraros; Sílvia Cufí; Sílvia Flaquer; Francesca Llopis-Puigmarti; Eulalia Pujol-Amado; Bruna Corominas-Faja; Elisabet Cuyàs; Rosa Ortiz; Eugeni Lopez-Bonet; Bernardo Queralt; Raquel Guardeño; Begoña Martin-Castillo; Josep Roig; Jorge Joven; Javier A Menendez
Journal:  Oncotarget       Date:  2014-04-15

6.  Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.

Authors:  Payam Delfani; Linda Dexlin Mellby; Malin Nordström; Andreas Holmér; Mattias Ohlsson; Carl A K Borrebaeck; Christer Wingren
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

7.  Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays.

Authors:  Anna S Gerdtsson; Linda Dexlin-Mellby; Payam Delfani; Erica Berglund; Carl A K Borrebaeck; Christer Wingren
Journal:  Microarrays (Basel)       Date:  2016-06-08

Review 8.  Current applications of antibody microarrays.

Authors:  Ziqing Chen; Tea Dodig-Crnković; Jochen M Schwenk; Sheng-Ce Tao
Journal:  Clin Proteomics       Date:  2018-02-28       Impact factor: 3.988

9.  Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example.

Authors:  Sandra Page; Aybike Birerdinc; Michael Estep; Maria Stepanova; Arian Afendy; Emanuel Petricoin; Zobair Younossi; Vikas Chandhoke; Ancha Baranova
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

Review 10.  Proteomics and peptidomics: moving toward precision medicine in urological malignancies.

Authors:  Ashley Di Meo; Maria D Pasic; George M Yousef
Journal:  Oncotarget       Date:  2016-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.